Summit Securities Group’s DexCom DXCM Stock Holding History

Summit Securities Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,174	Closed	-$77.9K	–	1133
2025 Q4	$77.9K	Buy	1,174 +1,046	+817%	+$67.6K	0.01%	519
2025 Q3	$8.61K	Buy	+128	New	+$10.1K	﹤0.01%	881
2025 Q1	–	Sell	-61	Closed	-$4.74K	–	870
2024 Q4	$4.74K	Buy	+61	New	+$4.52K	﹤0.01%	518
2024 Q3	–	Sell	-53	Closed	-$6K	–	654
2024 Q2	$6K	Buy	+53	New	+$6.7K	﹤0.01%	476
2024 Q1	–	Sell	-31	Closed	-$4K	–	579
2023 Q4	$4K	Sell	31 -13	-30%	-$1.33K	﹤0.01%	575
2023 Q3	$4K	Sell	44 -87	-66%	-$9.81K	﹤0.01%	478
2023 Q2	$17K	Buy	+131	New	+$15.8K	﹤0.01%	668
2023 Q1	–	Sell	-1	Closed	–	–	929
2022 Q4	$0	Sell	1 -1,541	-100%	-$169K	﹤0.01%	1204
2022 Q3	$124K	Buy	+1,542	New	+$131K	0.01%	490
2022 Q2	–	Sell	-1,760	Closed	-$225K	–	1017
2022 Q1	$225K	Buy	+1,760	New	+$193K	0.03%	361

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Summit Securities Group's DXCM Position: Q1 2026 in Review

Summit Securities Group sold out of DexCom (DXCM) in Q1 2026, closing a stake of 1,174 shares — an estimated $77.9K sold.

Summit Securities Group first reported a position in DXCM in Q1 2022 and held it in 10 quarters. The position peaked at $225K in Q1 2022. 960 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Summit Securities Group reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
Summit Securities Group sold 1,174 DexCom shares in Q1 2026, an estimated $77.9K.
Summit Securities Group first reported a position in DexCom in Q1 2022 and held it in 10 quarters.
Summit Securities Group's DexCom position peaked at $225K in Q1 2022.
960 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.